What is Theravance Biopharma's D&A?

Theravance Biopharma (TBPH) reported D&A of $381K in Q1 2026.

How has Theravance Biopharma's D&A changed year-over-year?

Theravance Biopharma's D&A decreased by 7.7% year-over-year, from $413K to $381K.

What is the long-term trend for Theravance Biopharma's D&A?

Over 4 years (2021 to 2025), Theravance Biopharma's D&A has grown at a -23.7% compound annual growth rate (CAGR), from $4.8M to $1.63M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Theravance Biopharma TBPH D&A

D&A at other companies

Zevra Therapeutics, Inc.ZVRA

$368K-77.7%

LQD

Liquidia CorporationLQDA

$497K+10.2%

United TherapeuticsUTHR

$22.6M+14.1%

Aurinia PharmaceuticalsAUPH

$4.82M-0.8%

PrecigenPGEN

$1.1M+74.7%

Ultragenyx PharmaceuticalRARE

$8M-11.1%

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+67.5%

Enterprise value$642.72M+37.0%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:OtherDepreciationAndAmortization.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's D&A?: Theravance Biopharma (TBPH) reported D&A of $381K in Q1 2026.
How has Theravance Biopharma's D&A changed year-over-year?: Theravance Biopharma's D&A decreased by 7.7% year-over-year, from $413K to $381K.
What is the long-term trend for Theravance Biopharma's D&A?: Over 4 years (2021 to 2025), Theravance Biopharma's D&A has grown at a -23.7% compound annual growth rate (CAGR), from $4.8M to $1.63M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.